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Abstract
Background: cis-urocanic acid (cis-UCA) is an endogenous amino acid metabolite capable of transporting protons
from the mildly acidic extracellular medium into the cell cytosol. The resulting intracellular acidification suppresses
many cellular activities. The current study was aimed at characterizing the molecular mechanisms underlying
cis-UCA-mediated cytotoxicity in cultured cancer cells.
Methods: 5367 bladder carcinoma cells were left untreated or treated with cis-UCA. Cell death was assessed by
measuring caspase-3 activity, mitochondrial membrane polarization, formation and release of cytoplasmic histone-
associated DNA fragments, and cellular permeabilization. Cell viability and metabolic activity were monitored by
colorimetric assays. Nuclear labelling was used to quantify the effects of cis-UCA on cell cycle. The activity of the
ERK and JNK signalling pathways was studied by immunoblotting with specific antibodies. Phosphatase activity in
cis-UCA-treated cells was determined by assay kits measuring absorbance resulting from the dephosphorylation of
an artificial substrate. All statistical analyses were performed using the two-way Student’s t-test (p < 0.05).
Results: Here we report that treatment of the 5637 human bladder carcinoma cells with 2% cis-UCA induces both
apoptotic and necrotic cell death. In addition, metabolic activity of the 5637 cells is rapidly impaired, and the cells
arrest in cell cycle in response to cis-UCA. Importantly, we show that cis-UCA promotes the ERK and JNK signalling
pathways by efficiently inhibiting the activity of serine/threonine and tyrosine phosphatases.
Conclusions: Our studies elucidate how cis-UCA modulates several cellular processes, thereby inhibiting the
proliferation and survival of bladder carcinoma cells. These anti-cancer effects make cis-UCA a potential candidate
for the treatment of non-muscle invasive bladder carcinoma.
Background
cis-urocanic acid [cis-UCA; 3-(1H-imidazol-4-yl)prop-2-
enoic acid] is an endogenous metabolite of amino acid
histidine found in the mammalian skin after exposure to
ultraviolet radiation. cis-UCA is known to induce immu-
nosuppression in animals [1,2]. We have recently dis-
covered that cis-UCA is capable of transporting protons
from the mildly acidic extracellular medium into the
cytosol of cancer cells, thereby inhibiting the prolifera-
tion of several human tumour cell lines [3,4], and indu-
cing apoptosis in vitro and in tumour xenografts in vivo
[4]. Intracellular acidification is known to affect cell
proliferation [5,6] and to promote apoptosis [7,8]. This
n e wm o d eo fa c t i o no fc i s - U C A ,w h i c hw eh a v en a m e d
as the protodynamic action, constitutes a novel concept
of anticancer therapy. The transportation and release of
protons into the cytosol is based on the unique second
acid dissociation constant (pKa2)o fc i s - U C A[ 9 ] ,a n di t
is inherently independent of enzymes and membrane
receptors.
The use of cis-UCA as an anticancer agent against
non-muscle-invasive bladder cancer has previously been
evaluated in cultured moderately and poorly differen-
tiated human transitional bladder cancer cells using a
short term (up to 2 h) pulse treatment model in vitro,
which mimics the clinical intravesical chemotherapy
regimen [3]. In the current study, we aimed at charac-
terizing the molecular mechanisms underlying cis-UCA-
mediated cytotoxicity to cultured cancer cells. Here we
show that cis-UCA extends a wide range of effects on
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carcinoma cells with 2% cis-UCA induced a combina-
tion of apoptotic and necrotic cell death. In addition,
metabolic activity of the 5637 cells was rapidly impaired,
and cell cycle arrest was induced at 1-3% cis-UCA.
Importantly, we were able to show that cis-UCA pro-
motes the ERK and JNK signalling pathways. Rather
than due to increased kinase activation, the observed
effect seemed to be caused by a decrease in both tyro-
sine and serine/threonine phosphatase activities that act
as critical regulators of the ERK and JNK signalling
pathways. Within the scope of the protodynamic therapy
concept, our study suggests a novel mechanism for cis-
UCA-induced inhibition of cancer cell survival, based
upon compromised signalling and metabolic functions
and cell cycle arrest leading to apoptotic and necrotic
cell death. Our observations give incentive to further
studies addressing the efficacy of cis-UCA in intravesical
treatment of bladder carcinoma.
Methods
Cell culture and treatments
5637 bladder carcinoma cell were cultured as monolayers
in logarithmic growth phase in Dulbecco’s Modified
Eagle medium (Invitrogen, Paisley, UK) supplemented
with 10% fetal bovine serum (Invitrogen) and penicillin-
streptomycin (Sigma-Aldrich, St. Louis, MO, USA) in a
humidified incubator at 37°C and 5% CO2. The medium
was adjusted to pH 6.5 or 7.4 with NaOH after the addi-
tion of cis-UCA (BioCis Pharma, Turku, Finland) [3] or
PIPES (Sigma-Aldrich) as osmotic control. For inhibition
of the JNK and ERK kinase pathways, the cells were incu-
bated with the JNK inhibitor SP600125 (10 μM; Sigma-
Aldrich) or the MAPKK inhibitor PD98059 (40 μM;
Sigma-Aldrich) for 40 min before cis-UCA treatment. In
the protein phosphatase activity measurements, calyculin
A (Calbiochem/Merck, Darmstadt, Germany) was used at
20 nM and sodium orthovanadate (New England Biolabs)
at 1 mM for 2 h during the cis-UCA pulse to inhibit
phosphatases.
Measurement of intracellular pH
Two million cells were incubated in 1 ml of Hank’s
balanced salt solution (HBSS; Sigma-Aldrich), pH 7.4,
containing 0.35 μM2 ’,7’-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein (BCECF, acetoxymethyl ester; Mole-
cular Probes) at room temperature for 30 min, washed
twice in HBSS, and resuspended in 0.5 ml of physiologi-
cal saline. Various concentrations of cis-UCA were
added to HBSS buffer, the solutions were adjusted to
pH 6.5 or 7.4 and 300 μl of each solution was mixed
with 15 μl of the BCECF-labelled cell suspension. The
cells were analysed by flow cytometry (FACScan, BD
Pharmingen) within 1 h. Fluorescence intensities were
calibrated by analysing BCECF-labelled cells in 50 mM
potassium phosphate buffers, pH 6.2-7.8, containing 43
mM KCl and 10 μM nigericin (Molecular Probes).
Detection of cell death
After the 2-h cis-UCA pulse in indicated concentrations
and a subsequent recovery time of 20 h without cis-UCA,
both the floating and attached cells were collected by
trypsinization. Caspase-3 activation was detected accord-
ing to manufacturer’s protocol (BD Pharmingen). Briefly,
the cells were washed, fixed, permeabilized and labelled
with phycoerythrin-conjugated anti-active caspase-3 anti-
body. After labelling, the cells were washed and analysed
by flow cytometry (FacsCalibur, BD Pharmingen). Mito-
chondrial membrane potential was measured by seques-
tering of tetramethyl rhodamine methyl ester (TMRM) to
cells. The cells were incubated in 50 nM TMRM (Invitro-
gen) in PBS for 15 min at 37°C, washed and analysed by
flow cytometry. The TMRM-negative population was
gated as cells with lost mitochondrial membrane poten-
tial. Formation of cytoplasmic and released histone-asso-
ciated DNA fragments was assayed in triplicate cell
lysates and cell culture supernatants, respectively, with a
photometric enzyme immunoassay (Cell Death Detection
ELISA
PLUS, Roche, Mannheim, Germany) according to
the manufacturer’s instructions. Background absorbance
of the reaction buffers at the corresponding pH without
cells and the absorbance values of each well at a non-
specific reference wavelength were subtracted. For detec-
tion of necrotic cell death, the cells were placed on ice
and incubated with 50 μg/ml propidium iodide (PI;
Sigma-Aldrich) in PBS for 10 min. The samples were
analysed directly by flow cytometry for PI labelling indi-
cative of cellular permeabilization. Nuclear morphology
of the cells was investigated by labelling with DAPI. The
cells were fixed with 3% paraformaldehyde for 15 min at
room temperature and resuspended in PBS. Cytospin
preparates were made and the samples were mounted
with DAPI Vectashield (Vector Laboratories). The sam-
ples were analysed with Zeiss LSM confocal microscope
(405 nm excitation, 420 nm long-pass emission filtering,
40× oil immersion objective).
Detection of cell survival and metabolic activity
The survival of cells was quantified as the number of
viable cells by using a colorimetric method (CellTiter 96
AQueous One Solution Cell Proliferation Assay; Promega)
that quantifies the formation of a formazan product from
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) in live cells. The
absorbance at 490 nm was read in flat-bottom 96-well
plates at 4 h after the addition of the assay reagent.
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tracted from the measurements.
For measurement of metabolic activity, the MTS assay
was done in triplicate samples on 24-well plates. After a
2-h cis-UCA pulse at pH 6.5, the cell medium was chan-
ged and the assay reagent was added. The absorbance
was measured hourly at 490 nm up to 4 h of incubation
at 37°C. Background absorbance (medium without cells)
was subtracted from the measurements.
Cell cycle analysis
For cell cycle analysis, the cells were synchronized by
serum starvation for 48 h, treated with cis-UCA for 2 h
and let to recover for the next 24 h. After collection, the
cells were disrupted and the nuclei labelled for DNA
content with PI by resuspension to sodium citrate buffer
(40 mM Na-citrate, 0.3% Triton X-100, 50 μg/ml PI).
After incubation at room temperature for 10 min, the
samples were immediately analysed by flow cytometry.
Western blotting
Whole-cell lysates were prepared by lysing the cells in
Laemmli sample buffer and boiling for 10 minutes after
which proteins were separated by SDS-PAGE. Western
blotting was performed using antibodies against p44/42
ERK1/2, phosphorylated Thr202/Tyr204 ERK1/2, p46/54
JNK1/2, phosphorylated Thr183/Tyr185 JNK1/2 (all from
Cell Signaling Technologies), and actin (Sigma-Aldrich).
Secondary antibodies were purchased from Promega.
Measurement of phosphatase activity
Analysis of serine/threonine phosphatase 2A and tyro-
sine phosphatase activity was conducted with assay kits
(product no. V2460 and V2471, respectively; Promega)
according to manufacturer’s protocol. In this assay, cell
lysate is added on artificial phosphorylated substrates,
and the generation of free phosphate is determined by
measuring the absorbance of a complex formed by
phosphate, molybdate, and malachite green [10-12].
Statistical analysis
The statistical significance of differences in the data was
calculated with a two-way Student’st - t e s t ,w i t hp<0 . 0 5
considered to indicate significant differences.
Results
cis-UCA induces intracellular acidification in 5637 bladder
carcinoma cells
According to the protodynamic concept, the prerequisite
of the anticancer action of a cell-permeable weak acid
such as cis-UCA is the induction of intracellular acidifi-
cation. We have recently reported that cis-UCA impairs
the survival of 5637 bladder cancer cells at pH 6.5 but
not at pH 7.4 in vitro [3]. To demonstrate that cis-UCA
is also able to decrease the intracellular pH, the 5637
cells were labelled with a pH sensitive fluorescent probe
BCECF and treated with various concentrations of cis-
UCA. In these experiments, dose-dependent acidifica-
tion by up to around 0.8 pH units was seen within 1 h
after the addition of cis-UCA at pH 6.5 but only by less
than 0.2 units at pH 7.4 (Figure 1), confirming the pH-
lowering effect of cis-UCA in bladder cancer cells. All
subsequent experiments in this study were performed at
pH 6.5 unless otherwise indicated.
cis-UCA induces both apoptotic and necrotic cell death in
5637 bladder carcinoma cells
Next, we examined the mechanisms of cell death in cis-
UCA-treated 5637 cells. A 2-h pulse treatment model,
which we have previously established [3], was used in
these studies. Briefly, 5637 cells were first incubated for
2hi nt h ep r e s e n c eo f0 - 4 %c i s - U C A ,f o l l o w e db ya2 0 - h
recovery without cis-UCA. We were able to detect for-
mation of cytoplasmic DNA-histone complexes indicative
of apoptotic cell death after 2% cis-UCA treatment at pH
6.5, but not at pH 7.4 (Figure 2A). In the mildly acidic
extracellular pH 6.5, also mitochondrial depolarization
(Figure 2B) and activation of the caspase-3 (Figure 2C)
were detected in cis-UCA-treated cells. These events are
typical of apoptotic cell death. However, cell permeabili-
zation indicated by propidium iodide labelling of the cells
occurred with 2% cis-UCA, suggesting that cis-UCA also
induces necrotic cell death (Figure 2D). This result
was supported by the observation that the amount of
Figure 1 cis-UCA induces intracellular acidification in 5637
bladder carcinoma cells. 5637 cells were labelled with BCECF prior
to treatment with cis-UCA at indicated concentrations in buffer
solutions adjusted to pH 7.4 or pH 6.5. After one hour the samples
were analysed by flow cytometry for intracellular pH.
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extracellular medium, increased with 2% and 4% cis-
UCA (data not shown). To eliminate the possibility that
these effects were caused by increased extracellular
osmolality due to high concentrations of cis-UCA, cells
were treated with an equimolar concentration of PIPES,
which is otherwise nontoxic to cells. In these experi-
ments, PIPES affected neither cell viability nor cellular
markers of apoptosis and necrosis (Figure 2).
To further analyse the biochemical events that take
place after 2% cis-UCA treatment, the nuclei were
labelled with DAPI and imaged by confocal microscopy
(Additional file 1: Figure S1). The results showed that a
large fraction of the cis-UCA-exposed 5637 cells dis-
played nuclei with characteristic apoptotic features,
including nuclear condensation and fragmentation. To
investigate caspase signalling upstream of caspase-3, the
activation-induced cleavage of caspase-8 was monitored
by Western blotting. Interestingly, we were unable to
detect caspase-8 cleavage, indicating that caspase-8 is
not activated in response to cis-UCA (data not shown).
This suggests that the extrinsic apoptotic pathway is
probably not involved in cis-UCA-induced cell death.
A modest cleavage of poly(ADP-ribose) polymerase-1
(PARP1) after treatment with 2% cis-UCA was detected
(data not shown), suggesting that in our experimental
setup, the cleavage of PARP1 is more likely to indicate
general cellular stress than progression of classical apop-
totic cell death.
5637 bladder carcinoma cells enter cell cycle arrest in
response to cis-UCA
As cis-UCA was able to trigger cell death, we sought to
determine whether cell cycle progression of the 5637
Figure 2 cis-UCA induces both apoptotic and necrotic cell death in 5637 bladder carcinoma cells. The cells were treated with indicated
concentrations of cis-UCA in buffer solutions adjusted to pH 7.4 or pH 6.5 for 2 h and let to recover in the absence of cis-UCA for 20 h. The cell
culture supernatants and cell lysates were analysed for formation of cytoplasmic histone-associated DNA fragments with a photometric enzyme-
immunoassay (A.). Alternatively, the cells treated with cis-UCA or PIPES (corresponding to 2% cis-UCA equimolar concentration) at pH 6.5 were
collected and labelled with TMRM for mitochondrial membrane potential (B.), analysed for caspase-3 activation (C.) or labelled with PI for cell
permeabilization as a measure of non-apoptotic cell death (D.). The samples were analysed by flow cytometry (Mean ± SEM; n = 3; Student’s
t-test * p < 0.05, ** p < 0.01, *** p < 0.001). The pictures are representative of two independent experiments.
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cells were synchronized to G0/G1 by serum starvation,
and the nuclei were analysed after the 2-h cis-UCA
pulse followed by 24-h recovery for DNA content by PI
labelling and flow cytometry. Interestingly, already 1%
cis-UCA induced G2/M block, as the cells accumulated
in this phase (Figure 3). Higher concentrations of cis-
UCA slightly increased the fraction of cells in the G0/
G1 phase, potentially indicating a block at the cell cycle
entry after synchronization. In addition, the higher con-
centrations are also likely to induce a general cell cycle
block due to short-circuits in cell cycle control. Western
blotting studies showed that cis-UCA does not cause
the accumulation of the cyclin-dependent kinase inhibi-
tors p21(WAF1/Cip1) and p27(Kip1), which were highly
expressed already in untreated 5637 cells (data not
shown), indicating that the arrest is a consequence of
general disturbances in cell control mechanisms rather
than specific triggering of emergency break mechanisms,
such as expression of p21 or p27.
cis-UCA reduces metabolic activity and promotes ERK and
JNK signalling in 5637 bladder carcinoma cells
The metabolic activity of the 5637 cells was followed for
4 h after the 2-h cis-UCA pulse using a MTS assay.
A clear inhibition of the cumulative cellular reducing
power was monitored by hourly measurements after 2%
and 3% cis-UCA treatments (Figure 4A) without any
visible effects on cell viability at these early time points.
To study whether the observed metabolic inhibition was
associated with activation of any major signalling path-
ways, we measured the effects of cis-UCA on stress and
mitogen-inducible protein kinases. For this purpose, we
collected whole-cell lysates immediately after the 2-h
pulse with 2% cis-UCA and analysed the phosphoryla-
tion and overall expression levels of ERK1/2 and JNK1/2
by Western blotting. Interestingly, we detected a marked
increase in the phosphorylated forms of ERK1/2 and
JNK2 in response to cis-UCA treatment (Figure 4B),
suggesting strong activation of these pathways. In con-
trast, the phosphorylation of JNK1 was only increased to
Figure 3 Cell cycle progression of 5637 bladder carcinoma cells is inhibited in response to cis-UCA. The cells were synchronized, treated
with 0-3% cis-UCA or PIPES (corresponding to 3% cis-UCA equimolar concentration) for 2 h, and let to recover in the absence of treatments for
24 h. After incubation the collected cells were disrupted in sodium citrate buffer and the PI labelled nuclei were analysed by flow cytometry for
DNA content. Cell cycle phases were gated and the percentage of cells in each phase quantified. Statistical analysis of the percentage of nuclei
in G2/M cell cycle phase is presented (Mean ± SEM; n = 6; Student’s t-test n.s. non-significant, ** p < 0.01, *** p < 0.001).
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lation of Akt was not affected by cis-UCA (data not
shown).
It is well known that the small-molecule inhibitors
SP600125 and PD98059 are able to prevent the activity
of JNK and ERK, respectively. To investigate if we could
counteract the effect of cis-UCA on cell viability by
inhibiting JNK and ERK1/2, the 5637 cells were incu-
bated with cis-UCA in the presence of SP600125 and
PD98059, after which cellular viability was measured by
MTS assay. Surprisingly, the inhibitors were unable to
prevent cis-UCA-mediated loss of cellular viability (Fig-
ure 4C). The inhibitors alone were non-toxic to the
cells (Figure 4C and data not shown). Moreover,
SP600125 and PD98059 did not affect the cis-UCA-
mediated increase in phosphorylation of ERK and JNK
(data not shown). Together, these data indicate that
cis-UCA is not capable of directly activating these
signalling pathways.
cis-UCA inhibits cellular phosphatase activity in 5637
bladder carcinoma cells
T h u sf a rw eh a v ed e m o n s t r a t e dt h a tt h ea c t i o no f
cis-UCA in 5637 cells is associated with increased phos-
phorylation of ERK1/2 and JNK2, but the inhibition of
these kinase pathways did not prevent cis-UCA-induced
decrease in cell survival (Figure 4C). To provide an
explanation for these unexpected data, we hypothesized
that the cis-UCA-induced intracellular acidification
would negatively regulate the phosphatase activity in
cancer cells, which would then lead to enhanced protein
phosphorylation of ERK1/2a n dJ N K 2 .T oi n v e s t i g a t e
this possibility, we analysed the activity of protein tyro-
sine phosphatases as well as serine/threonine phospha-
tase 2A in 5637 cell lysates prepared immediately after
the 2-h cis-UCA pulse. We detected a significant
decrease in serine/threonine phosphatase 2A activity
with 1-2% cis-UCA as well as a decreased activity
towards the two tested tyrosine phosphatase substrate
peptides with 0.5-2% cis-UCA (Figure 5A-C). These
results suggest that cis-UCA indeed inhibits serine/
threonine and protein tyrosine phosphatase activity. It is
therefore likely that the reduced phosphatase activity
indirectly promotes the major MAPK signalling path-
ways.
Discussion
In the present study, we aimed at characterizing the cell
signalling processes that contribute to the previously
reported cytotoxic effects of cis-UCA in cultured bladder
cancer cells [3]. The 2-h pulse treatment model in the
Figure 4 Intracellular acidification by cis-UCA activates the ERK
and JNK signalling pathways. (A.) The 5637 cells were treated
with 0-3% cis-UCA at pH 6.5 for 2 h after which the culture medium
was changed and the MTS/PMS reagent added to cells. Absorbance
(490 nm) was measured hourly up to 4 h (Mean ± SEM; n = 3,
representative of two independent triplicate experiments). (B.) The
5637 cells were treated with 2% cis-UCA at pH 6.5. After harvesting,
whole cell lysates were prepared, and ERK and JNK activity was
monitored by Western blotting against phospho-ERK, ERK, phospho-
JNK, and JNK. Actin expression was measured as loading control.
(C.) The cells were treated with JNK inhibitor SP600125 or ERK
inhibitor PD98059 for 40 min before addition of 2% cis-UCA at pH
6.5 for the following 2 h. Twenty hours later, cell viability was
monitored by the MTS assay (Mean ± SD; n = 3).
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cancer cells was chosen to mimic conventional clinical
intravesical instillation chemotherapy treatment of
patients with non-muscle-invasive bladder cancer. We
found that the protodynamic use of cis-UCA initiates
intracellular acidification in bladder carcinoma cells,
followed by modulation of several key processes includ-
ing cell cycle, metabolic activity, and cell death. A 2-h
pulse with 2% cis-UCA approximately triples the amount
of apoptosis of the control level, but also promotes non-
apoptotic cell death. The continuum between cell death
responses can be both a consequence of secondary
necrosis due lost selective membrane permeability in
apoptotic cells (upon prolonged incubation), as well as
the triggering of unspecific cell death within the cell
population. When we analysed caspase activity and other
markers of apoptosis, we found that cis-UCA induces the
activation of caspase-3, causes mitochondrial depolariza-
tion and formation of cytoplasmic DNA-histone com-
plexes, while caspase-8 activation is not affected. In
addition, 2-3% cis-UCA treatment results in PARP1 clea-
vage. These data suggest that cis-UCA-mediated apopto-
sis occurs via the intrinsic apoptotic pathway, concurring
with the idea of the mitochondrial pathway as the major
mediator of stress-induced apoptosis.
Importantly, cis-UCA not only caused cell death, but
also had cytostatic effects. We found that 2-3% cis-UCA
severely impaired the metabolic activity of the 5637
bladder carcinoma cells. This effect could be detected
already 1 h after the cis-UCA pulse, and the relative dif-
ference compared to the untreated cells grew over time.
The induction of both apoptotic and partly necrotic
responses in the bladder carcinoma cells reflect the
effects of cis-UCA treatment on cellular metabolism, as
mitochondrial functions play a central role in triggering
of both apoptotic and necrotic cell death. Moreover, cell
cycle progression was disturbed by cis-UCA, but it did
not seem to be mediated by p53-dependent mechan-
isms, as we found that the compound had no effect on
the cyclin-dependent kinase inhibitors p27 and p21,
both of which are important mediators of p53-depen-
dent cell cycle arrest. However, as the untreated 5637
bladder carcinoma cells expressed high levels of the p27
and p21 in the absence of cell cycle arrest, these inhibi-
tory pathways may be impaired in this cancer cell type.
In addition to clarifying which cellular processes are
targeted by cis-UCA, we were also interested in analys-
ing the signalling pathways contributing to these effects.
We discovered that the 5637 bladder carcinoma cells
show very low endogenous activities of ERK, JNK, and
Akt. Interestingly, cis-UCA remarkably increased the
activity of both ERK and JNK, whereas the levels of
phosphorylated Akt remained unchanged. This suggests
that ERK and JNK pathways may mediate some of the
Figure 5 cis-UCA inhibits phosphatase activity in 5637 bladder
carcinoma cells. To measure the effect of cis-UCA on phosphatase
activity, the 5637 cells were treated with 0.5-2% cis-UCA or
phosphatase inhibitors, 20 nM calyculin A and 1 mM orthovanadate
(Na2VO4), at pH 6.5 for 2 h. The cells were subsequently lysed,
incubated with the substrate peptide for Ser/Thr phosphatase 2A
(RRA(pT)VA; A.), or Tyr phosphatases (END(pY)INASL; B. and DADE
(pY)LIPQQG; C.) for 30 min, and the absorbance was measured 20
min after the end of the substrate reaction (Mean ± SD; n = 3;
Student’s t-test * p < 0.05, ** p < 0.01, *** p < 0.001). Ser/Thr
phosphatase 2A activity (A.) was measured in a reaction buffer
without MgCl2 to inhibit phosphatase 2C activity.
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ERK and JNK pathways failed to block the effect of cis-
UCA on cell viability. This indicated that cis-UCA
might not promote ERK and JNK by activating their
upstream regulators, but indirectly by inhibiting the
phosphatases that inactivate these kinases. Remarkably,
our measurements showed that the activity of protein
tyrosine phosphatases and type 2A serine/threonine
phosphatases was significantly decreased by 1-2% cis-
UCA. Therefore, inhibition of phosphatase activity
represents a novel mechanism for cis-UCA-mediated,
intracellular acidification-dependent cytotoxic effects.
T h ei d e ao fu s i n gap h o s p h a t a s e - i n h i b i t i n ga g e n ta sa
means to kill cancer cells is relatively uncommon, as
synthetic phosphatase inhibitors are known for their
high, unspecific toxicity and tumour-promoting poten-
tial [13]. Nevertheless, natural products such as the pro-
tein phosphatase 2A inhibitor cantharidin have been
shown to display anti-tumour effects [14]. Mutations of
the H-Ras proto-oncogene increase phosphatase 2A
activity and sensitize cancer cells to okadaic acid-
induced apoptosis [15], the effects of cis-UCA might not
be linked to these mutations, as the H-Ras mutation
seems to be rather rare in bladder cancer [16]. However,
transitional cell carcinoma of human urinary bladder
has been reported to harbour H-Ras mutations [17],
leaving the potential role of H-Ras in this context open.
In this study, we have characterized the molecular
mechanisms underlying the anticancer effects of cis-UCA.
In addition to causing apoptotic and necrotic cell death,
cis-UCA also interferes with the metabolic activity and cell
cycle progression of cancer cells. It is evident that the pro-
todynamic action of cis-UCA has no selectivity against
tumour cells versus normal cells. Instead, the potential of
cis-UCA as an anticancer drug is based on the fact that
solid tumour cells typically form a transmembrane pH
gradient by acidifying the extracellular microenvironment,
usually to around pH 6.7, while maintaining normal,
slightly alkaline intracellular pH [18]. In these conditions,
the tumour can be killed by intracellular acidification-
induced injury caused by a protodynamic agent transport-
ing hydrogen ions into the cytosol in a pH-sensitive
manner. In the normal tissues, including the blood, the
cytotoxicity of cis-UCA would be “neutralized”, because
no hydrogen ion transportation would occur in the
absence of the transmembrane pH gradient.
Extensive preclinical evidence has confirmed that cis-
UCA is neither mutagenic nor locally irritating. A single
intravesical dose of up to high concentrations of 6%
(60 mg/ml; 19) and 12% (120 mg/ml; Laihia et al.
unpublished) cis-UCA instilled in the rat urinary bladder
for 1 or 2 h, respectively, is well tolerated with no signs
of clinical abnormality or macroscopic bladder damage.
In addition, there is no apparent local or systemic
toxicity in dogs treated with 2-12% cis-UCA intravesi-
cally twice a week for 1 h per instillation for 4 weeks
(Laihia et al. unpublished). In light of the insignificant
toxicity of cis-UCA, our cellular data, demonstrating
marked cytotoxicity in bladder carcinoma cells, suggest
that protodynamic therapy with cis-UCA could be a fea-
sible intravesical treatment for bladder cancer. To con-
clude, our results elucidate how cis-UCA modulates
numerous key cellular processes, thereby compromising
the viability of bladder carcinoma cells. The detailed
mechanisms behind phosphatase inactivation and mito-
chondrial permeabilization by cis-UCA treatment will be
topics of our future studies.
Conclusions
In conclusion, our study describes the cytotoxic and
cytostatic effects of cis-UCA in bladder carcinoma cells,
and elucidates the underlying molecular mechanisms.
The protodynamic action of cis-UCA leads to decreased
intracellular pH, impaired metabolic activity and
increased in cell death. Importantly, cis-UCA inhibits
the activity of serine/threonine and tyrosine phospha-
tases, thereby indirectly promoting ERK and JNK activ-
ity. In the future, the protodynamic action of cis-UCA
could be utilized in intravesical therapy to compromise
the viability of bladder carcinoma cells.
Additional material
Additional file 1: Figure S1: Apoptotic nuclear morphology
following 2% cis-UCA treatment. The control cells and the cells treated
with 2% cis-UCA (pH 6.5) were fixed, labelled with DAPI and analysed by
confocal microscopy for nuclear morphology (40× objective). The
pictures are representative of two independent experiments.
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